Tag: IPO Regulations
Income indicators and risks for pharma IPOs
How income indicators and sales expenses impact risks in pharmaceutical IPOs under regulatory scrutiny
How income indicators and sales expenses impact risks in pharmaceutical IPOs under regulatory scrutiny
Walter Chia, the chief representative officer for Asia-Pacific at INTA, elaborates on factors shaping IP across the region
Follow us on LinkedIn